Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01870297 | A Study of LY3025876 in Participants With Diabetes | PHASE1 | COMPLETED | 72 | — | — | Jun 1, 2013 | Dec 1, 2014 | Jan 24, 2019 | 4 | United States |
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| Arm | Type | Description |
|---|---|---|
| LY3025876 | EXPERIMENTAL | Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days. |
| Placebo | PLACEBO_COMPARATOR | Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days |
| LY3025876 + Liraglutide | EXPERIMENTAL | Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks. |
| Placebo + Liraglutide | PLACEBO_COMPARATOR | Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3025876 | DRUG | Administered SQ |
| Placebo | DRUG | Administered SQ |
| Liraglutide | DRUG | Administered SQ |
Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM) as determined by the investigator, controlled with diet or exercise alone or on a stable dose of metformin for at least 30 days * Have a body mass index (BMI) greater than or equal to 23 and less than or equal to 45 kilograms per sq...